ANNUAL COST OF TREATMENT OF SPINAL MUSCULAR ATROPHU PATIENTS IN TURKEY

Author(s)

Kockaya G1, Oguzhan Ergın G2, Çalışkan Z3
1ECONiX, Ankara, Turkey, 219 Mayıs University, Samsun, Turkey, 3Hacettepe University, Ankara, Turkey

OBJECTIVES : Spinal muscular atrophy (SMA) is a genetic disorder impacting the nervous system which controls voluntary muscle movement. SMA classified as early onset (SMA 1-2) and late onset (SMA 3-4). Symptoms of SMA are correlated with earlier age onset. It is estimated that there are close to 3000 SMA patients in Turkey due high consanguineous marriage and lack of screening. The aim of the study is to understand current best supportive care treatment protocol and cost of treatment with payer perspective including direct cost in Turkey

METHODS : A literature search has been conducted. Depending on the search, an expert opinion questionare for understading the healthcare utilization had been prepared. Questionate was applied to 4 SMA experts from Ankara, Istanbul, Izmir and Adana cities. Outcome of questionare calculated with reimbursement price of Social Security Institution(SGK) to understand direct cost to Turkish government based reimbursement system.

RESULTS : Experts didnt report SMA 4 patients healthcare utilization due the lack of patient experiences in Turkey. Annual cost of SMA 1 patients was calculated as 32.987 TL for the first year and 22.887 TL for following years. Annual cost of SMA 2 patients was calculated as 15.010 TL for first year and 4.910 TL for following years. Annual cost of SMA 3 patients calculated as 12.843 TL for first year and 2.743 TL for following years.

CONCLUSIONS : It is reported that direct cost of best supportive care for SMA patients is an important amount for Turkey`s government based reimbursement system. Indirect cost of SMA patients to patient families and society was not calculated in the analysis. If the indirect cost might be included, total cost of illness of SMA may be significantly higher than calculated direct cost. Further studies need to be conducted for better understanding of treatment protocol and cost of treatment of SMA patients.

Conference/Value in Health Info

2019-11, ISPOR Europe 2019, Copenhagen, Denmark

Code

PRO49

Topic

Economic Evaluation, Health Policy & Regulatory

Topic Subcategory

Budget Impact Analysis, Reimbursement & Access Policy, Value of Information

Disease

Rare and Orphan Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×